Adaptimmune Therapeutics plc (ADAP) Social Stream
Adaptimmune Therapeutics PLC (ADAP) Price Targets From Analysts
The tables below show the price targets and recommendations analysts covering ADAP.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Current Price||Upside Potential|
ADAP reports an average of 143.26% for its upside potential over the past 71 days.
|Date||Number of Analysts||Highest Target Price||Lowest Target Price||Average Target Price||Share Price||Upside Potential|
ADAP Broker Recommendations Summary
|Average Broker Rating||Strong Buy||Buy||Hold||Sell||Strong Sell||Analysts Issuing Recs|
The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ADAP as an investment opportunity.
- Adaptimmune Therapeutics PLC's variance in analysts' estimates is lower than 6.88% of all US stocks.
- Adaptimmune Therapeutics PLC's average analyst price target is higher than 16.78% of Healthcare stocks.
- To contextualize these metrics, consider that out of stocks in the small market cap category, Adaptimmune Therapeutics PLC's upside potential (average analyst target price relative to current price) is greater than 77.97% of them.
- ADAP has a greater number of analysts covering the stock than 65.9% of stocks in the small market cap category.
Is ADAP a Buy, Hold or Sell? See the POWR Ratings now!